drugset

drugset / Trial / NCT01833494

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01833494 ↗

Phase 3 Completed 161 enrolled Kissei Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

Timeline

Start: 2013-03-18
Primary completion: 2014-08
Completion: 2014-08-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PA21	Unknown	—	—

Indications